Trials / Completed
CompletedNCT00326183
Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)
An Open, Multicenter Study of the Safety and Tolerability of VAQTA(TM) and ProQuad(TM) in Healthy Children 12 to 23 Months of Age
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1,800 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 12 Months – 17 Months
- Healthy volunteers
- Accepted
Summary
Two doses each of Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella \[Oka/Merck\] Virus Vaccine Live will be given concomitantly or non-concomitantly. Safety data will be collected following each vaccination.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | VAQTA® | 0.5 ml injection VAQTA®; 2nd 0.5 ml injection VAQTA® 24 week period of treatment. |
| BIOLOGICAL | ProQuad | 0.5 ml injection ProQuad; 2nd 0.5 ml injection ProQuad®. 24 week period of treatment. |
Timeline
- Start date
- 2007-03-26
- Primary completion
- 2008-01-15
- Completion
- 2008-01-15
- First posted
- 2006-05-16
- Last updated
- 2019-02-04
- Results posted
- 2008-11-20
Source: ClinicalTrials.gov record NCT00326183. Inclusion in this directory is not an endorsement.